Cellosaurus G-401 (CVCL_0270)

Cell line name G-401
Synonyms G401; G 401
Accession CVCL_0270
Resource Identification Initiative To cite this cell line use: G-401 (RRID:CVCL_0270)
Comments Problematic cell line: Misidentified. Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (PubMed=8382007).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K27me3 ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for SMARCB1 deletion (PubMed=28945250).
Disease Rhabdoid tumor of the kidney (NCIt: C8715)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_QW55 (G-401 BAF47)CVCL_J252 (G-401-Luc)CVCL_L269 (G401.6)
Sex of cell Male
Age at sampling 3M
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; ECACC; JCRB; PubMed=25877200

Penta D10,11
Penta E7
TH018,9.3 (ATCC; Cosmic-CLP; ECACC; JCRB)
9.3 (PubMed=25877200)
11 (PubMed=25877200)
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/g/cell-lines-detail-286.html

Garvin A.J., Re G.G., Tarnowski B.I., Hazen-Martin D.J., Sens D.A.
The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney.
Am. J. Pathol. 142:375-380(1993)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28945250; DOI=10.1038/ng.3958
Nakayama R.T., Pulice J.L., Valencia A.M., McBride M.J., McKenzie Z.M., Gillespie M.A., Ku W.L., Teng M., Cui K., Williams R.T., Cassel S.H., Qing H., Widmer C.J., Demetri G.D., Irizarry R.A., Zhao K., Ranish J.A., Kadoch C.
SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nat. Genet. 49:1613-1623(2017)

Cell line collections ATCC; CRL-1441
ECACC; 87042204
Cell line databases/resources CLDB; cl1409
CCRID; 3111C0001CCC000034
Cosmic-CLP; 907299
GDSC; 907299
IGRhCellID; G401
TOKU-E; 1303
Ontologies BTO; BTO:0002586
CLO; CLO_0003434
EFO; EFO_0002179
MCCL; MCC:0000161
Biological sample resources 4DN; 4DNSR6XERO32
BioSample; SAMN03470969
BioSample; SAMN03472819
Chemistry resources ChEMBL-Cells; CHEMBL3308394
ChEMBL-Targets; CHEMBL613509
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827165
GEO; GSM887017
GEO; GSM888086
GEO; GSM1669799
GEO; GSM1676299
GEO; GSM1701634
GEO; GSM2409659
GEO; GSM2409660
GEO; GSM2409661
GEO; GSM2409662
GEO; GSM2409663
GEO; GSM2495985
GEO; GSM2787352
Other Wikidata; Q54835347
Polymorphism and mutation databases Cosmic; 683682
Cosmic; 802044
Cosmic; 802245
Cosmic; 907299